18 FDG PET and PET-CT for the detection of bone metastases in patients with head and neck cancer. A meta-analysis

J Med Imaging Radiat Oncol. 2013 Dec;57(6):674-9. doi: 10.1111/1754-9485.12077. Epub 2013 Jun 24.

Abstract

Introduction: We performed a meta-analysis to evaluate (18) FDG PET/PET-CT for the detection of bone metastases in patients with head and neck cancer.

Methods: We calculated sensitivities, specificities, likelihood ratios, and constructed summary receiver operating characteristic curves for PET and PET-CT, respectively. We also compared the performance of PET/PET-CT with that of bone scintigraphy by analysing studies that had also used bone scintigraphy on the same patients.

Results: Across 9 PET studies (1621 patients) and 10 PET-CT studies (1291 patients), sensitivity and specificity of PET were 0.81 and 0.99, and of PET-CT were 0.89 and 0.99, respectively. In 5 comparative studies (1184 patients), sensitivity and specificity of PET/PET-CT were 0.85 and 0.98, and of bone scintigraphy were 0.55 and 0.98, respectively.

Conclusions: (18) FDG PET and PET-CT have high sensitivity and accuracy for the detection of bone metastasis in patients with head and neck cancer.

Keywords: 18FDG PET; bone metastases; head and neck neoplasms; meta-analysis.

Publication types

  • Comparative Study
  • Meta-Analysis

MeSH terms

  • Bone Neoplasms / diagnosis*
  • Bone Neoplasms / epidemiology
  • Bone Neoplasms / secondary*
  • Evidence-Based Medicine
  • Fluorodeoxyglucose F18*
  • Head and Neck Neoplasms / diagnosis*
  • Head and Neck Neoplasms / epidemiology*
  • Humans
  • Multimodal Imaging / statistics & numerical data
  • Positron-Emission Tomography / statistics & numerical data*
  • Prevalence
  • Radiopharmaceuticals
  • Reproducibility of Results
  • Risk Assessment
  • Sensitivity and Specificity
  • Tomography, X-Ray Computed / statistics & numerical data*

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18